



REPO TRIAL



RePo4EU

SEPTEMBER 26TH 2022
PRESS RELEASE

REPO-TRIAL inventions and technology licensed to Arega Medical

Professor Harald H.H.W. Schmidt –chairman of the department of Pharmacology and Personalised Medicine at Maastricht University and coordinator of the REPO-TRIAL and REPO4EU EU-funded projects– and Arega Medical recently signed a sub-licensing agreement which grants rights to Arega to use REPO-TRIAL inventions and technology for global commercial purposes.

Based on the network pharmacology concept, synergistic repurposed combination therapies are being developed and intended to become available for patients in need. The licensed patents relate to the treatment of ischemic stroke, both for the diagnosis and treatment of heart failure with preserved ejection fraction (HFpEF) and for resistant hypertension.

Prof. Harald Schmidt comments:

“Organ-agnostic systems medicine holds great promise to change medicine by moving from symptom-based disease definitions to causal ones, allowing precision therapy and cure. However, our ultimate goal is to achieve patient benefit and therefore, one needs go the extra mile of finding a commercial partner to ensure market entry. We are excited to have found Arega as a strategic partner in taking up technology stemming from both REPO4EU and its predecessor project, REPO-TRIAL.”

Teun Grooters, CEO Arega Medical comments:

“We are excited about this agreement, as the academic network pharmacology concept developed by Prof. Harald Schmidt allows to map underlying disease mechanisms and design targeted product combinations, treating the underlying disease processes instead of merely providing symptom relief. By combining drugs with a companion diagnostic which preselects patients with specific underlying disease mechanisms, we will be able to offer precision treatments to patients suffering from these complex diseases. Drug repurposing and precision treatments are, in our view, the answer to more effective therapies and to the continuous and increasing pressure on healthcare budgets, which has become one of the top priorities in healthcare globally.”

About REPO-TRIAL and REPO4EU

REPO-TRIAL is a €5.5M EU funded platform for developing a computerized (*in silico*) approach to optimise the efficacy and precision of drug repurposing trials. REPO-TRIAL has received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement No. 777111.

REPO4EU is a €23M EU-funded Euro-global platform for mechanism-based drug repurposing – from low precision drug therapy to high precision curative therapy– through real-world data, Artificial Intelligence and every step necessary from lab to phase II clinical. REPO4EU receives funding from the European Union's Horizon Europe research and innovation programme under grant agreement No. 101057619.

About Arega Medical

Arega Medical is a R&D healthcare company that focuses on development and commercialization of repurposed drugs for untreatable diseases. Arega aims to address the societal need for sustainable healthcare, as well as the patients' need for effective, tolerable and affordable therapies. Arega Medical has the expertise and experience to bridge the gap between fundamental science and patient access and needs.

Key contacts

For scientific inquiries, please get in touch with Prof. Harald Schmidt at hschmidt@ppmlab.net
For inquiries linked to Arega Medical, please contact Teun Grooters at teun.grooters@arega.com